Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage .

New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti_EGFR ,anti_angiogenic and kinase inhibitors .

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Colorectal Adenocarcinoma

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

About this study

Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti_EGFR targeted therapy between left colon and rectal cancer

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age above 18
Both sex
Performance status zero to one according to ECOG scale system
Histo-pathologial diagnosis adenocarcinoma of left colon or rectum.
Patients diagnosed with left colon and rectal cancer.
Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC.
Patients diagnosed with metastatic stage.
K-RAS wild type.

Exclusion criteria

Second malignancy
Histo-pathological types other than adenocarcinoma.
Right colon cancer patients.
Patients refused receiving anti_EGFR targeted therapy.
Patients with any abnormalities preventing to receive chemotherapy.
Early stages of colorectal cancer.
K-RAS mutant type.

Treatment and study plan

Primary outcomes

OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy

Time frame: Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022

Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment

Secondary outcomes

Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.

Time frame: The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022

Factors affecting response to targeted therapy

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Retrospective Study of Metastatic Left Colon and Rectal Cancer as Regard Treatment With Anti_EGFR Targeted Therapy

Acronym: EGFR

Important dates

Study start: 2015
Primary completion: 2022
Study completion: 2022
First posted: Oct 16, 2023
Registry last updated: Oct 16, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed